The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 February 2026•

1 min read

Citius Oncology Secures Exclusive EU Distribution for Lymphir with Unipha

FDA and Novo Nordisk logos above a laboratory scene with computer monitors, chemical structures, medicine bottles, and pills.

Citius Oncology, a subsidiary of Citius Pharmaceuticals, has announced an exclusive distribution agreement with Unipha. This strategic partnership aims to make Lymphir (denileukin diftitox-cxdl), its targeted immune therapy, available across the European Union and other non-U.S. markets. The agreement marks Citius Oncology's third international distribution collaboration, significantly expanding the global reach for its treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL). This move is poised to enhance Citius Pharmaceuticals' market presence and unlock new revenue streams. The expansion into the EU represents a key step in globalizing access to this critical therapy.